Clinical Trials - February 9, 2024
Elicera receives approval to initiate clinical Phase I/II-study
Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical phase I/II study CARMA in patients with B-cell lymphoma that no longer respond to standard treatment or have relapsed. “The treatment has the potential to become a very important alternative for those patients whose disease no longer respond to standard […]
Biotech Business - February 2, 2024
CombiGene discontinues preclinical development of lipodystrophy project
The company has decided to discontinue the preclinical development of the lipodystrophy project CGT2. After receiving data that was difficult to interpret during the course of the project, CombiGene conducted additional studies in 2023 to provide a basis for a correct assessment of the project. Now that these studies have been completed, the company can […]
Clinical Trials - January 31, 2024
Scandion Oncology announces Phase IIa data
The company has reported positive topline results from the ongoing Part 3 of the CORIST phase IIa colorectal cancer trial with the lead compound SCO-101. A preliminary analysis of the study data shows tumor reduction supporting combination with chemotherapy, substantially increased Progression Free Survival, high Clinical Benefit Rate and consistent safety and tolerability, states the […]
Clinical Trials - January 31, 2024
Alzinova announces phase 1b data
The company has announced the primary analysis of study data from Alzinova’s phase 1b clinical trial in Alzheimer’s disease with the vaccine candidate ALZ-101. The analysis confirms the top-line results and that ALZ-101 was well tolerated and safe, states the company. Furthermore, the analysis confirms a high frequency of immune response and that patients treated […]
